CD33 and acute myeloid leukemia: Gemtuzumab ozogamicin (GO), a humanized CD33 antibody conjugated to a calicheamicin-γ1 derivative via a hydrolyzable linker, demonstrated clinical activity when given with induction chemotherapy in newly diagnosed AML, with mixed results depending on disease subtype, cytogenetic risk, and patient age.